News & Events

IFM Therapeutics alongside Novartis has been shortlisted for the 16th annual Scrip Awards in the Best Partnership Alliance category. The two companies were nominated based on their September 2019 collaboration and exclusive option agreement for IFM’s cGAS/STING-focused subsidiary, IFM Due. The IFM Due subsidiary has two preclinical programs. The first is aimed at developing an orally available, small-molecule antagonists of STING that can block the pathway’s ability to stimulate excessive production of pro-inflammatory cytokines. The second program is working to develop small-molecule inhibitors of cGAS, which will block the pathway at a more upstream node.

The cGAS/STING (cyclic GMP-AMP Synthase, Stimulator of Interferon Genes) pathway functions within the innate immune system to sense cytosolic DNA, which is a signal of cellular danger, and then triggers a STING-dependent inflammatory response. Mutations that activate this pathway can cause a variety of serious autoinflammatory and autoimmune diseases in humans.

The Scrip Awards provide the pharmaceutical, biotech, and other allied industries an opportunity to acknowledge and applaud the work done to improve healthcare. Fourteen judges reviewed submissions and selected the more than 80 finalists across all 14 categories. The final winners will be announced at the virtual awards ceremony, which takes place Wednesday, December 2nd at 2:00 p.m. EST.

To join us virtually, you can register here.